Bengaluru, Karnataka, India, May 2026 — Abhijit Zutshi has been appointed as Chief Commercial Officer (CCO) at Syngene International Limited, effective 1 May 2026. As a member of the Executive Committee, he will play a pivotal role in driving the company’s next phase of growth and strengthening its global commercial strategy.
In his new role, Abhijit will lead Syngene’s end-to-end commercial function, including sales, client partnerships, marketing, brand building, digital initiatives, and account management, further enhancing the company’s global positioning across key markets.
Abhijit brings nearly 27 years of global pharmaceutical commercial experience, including a distinguished 25-year tenure at Biocon. Most recently, he served as Chief Commercial Officer – Generics, where he led both drug substance and drug product businesses, building a strong global team focused on generic formulations and driving international expansion.
His expertise spans sales, marketing, business development, portfolio management, and market entry strategy across both small and large molecule segments, positioning him as a seasoned commercial leader in the global life sciences industry.
Earlier in his career, he worked with Pfizer as a Product Specialist, where he played a key role in leading the India launch of the Zosyn brand, gaining early exposure to market development and brand strategy in the pharmaceutical sector.
Abhijit holds a degree in Pharmacy, an MBA, and is a graduate of the Leadership Development Program at Harvard Business School.
Commenting on the appointment, Peter Bains, Managing Director and CEO of Syngene International Limited, said:
“We are pleased to welcome Abhijit to Syngene’s leadership team. His depth of experience and strong track record in his domain will be instrumental as we continue to evolve our service offerings and enhance our value proposition for clients worldwide. This appointment reinforces our commitment to building a world-class leadership team capable of driving our next phase of sustainable growth.”
About Syngene International Limited
Syngene International Limited is a leading integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals sectors.
With over 8,300 employees, including 5,700+ scientists, and more than 3 million sq. ft. of specialized facilities across India and the United States, Syngene partners with nearly 400 global clients, including leading multinational companies such as BMS, GSK, Zoetis, and Merck KGaA, delivering innovation at scale while improving time-to-market and cost efficiency.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
